299 related articles for article (PubMed ID: 23347430)
1. Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.
Sanders DA; Ross-Innes CS; Beraldi D; Carroll JS; Balasubramanian S
Genome Biol; 2013 Jan; 14(1):R6. PubMed ID: 23347430
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
3. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells.
Madureira PA; Varshochi R; Constantinidou D; Francis RE; Coombes RC; Yao KM; Lam EW
J Biol Chem; 2006 Sep; 281(35):25167-76. PubMed ID: 16809346
[TBL] [Abstract][Full Text] [Related]
4. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
5. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
[TBL] [Abstract][Full Text] [Related]
7. ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.
Horimoto Y; Hartman J; Millour J; Pollock S; Olmos Y; Ho KK; Coombes RC; Poutanen M; Mäkelä SI; El-Bahrawy M; Speirs V; Lam EW
Am J Pathol; 2011 Sep; 179(3):1148-56. PubMed ID: 21763263
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer.
Gong C; Tsoi H; Mok KC; Cheung J; Man EPS; Fujino K; Wong A; Lam EWF; Khoo US
Oncogene; 2020 Apr; 39(15):3206-3217. PubMed ID: 32066877
[TBL] [Abstract][Full Text] [Related]
9. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
10. CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.
Al-Dhaheri M; Wu J; Skliris GP; Li J; Higashimato K; Wang Y; White KP; Lambert P; Zhu Y; Murphy L; Xu W
Cancer Res; 2011 Mar; 71(6):2118-28. PubMed ID: 21282336
[TBL] [Abstract][Full Text] [Related]
11. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
12. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
[TBL] [Abstract][Full Text] [Related]
13. JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
Gao WW; Xiao RQ; Zhang WJ; Hu YR; Peng BL; Li WJ; He YH; Shen HF; Ding JC; Huang QX; Ye TY; Li Y; Liu ZY; Ding R; Rosenfeld MG; Liu W
Mol Cell; 2018 Apr; 70(2):340-357.e8. PubMed ID: 29628309
[TBL] [Abstract][Full Text] [Related]
14. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
15. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
16. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
17. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
18. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.
Yamaga R; Ikeda K; Horie-Inoue K; Ouchi Y; Suzuki Y; Inoue S
Horm Cancer; 2013 Aug; 4(4):222-32. PubMed ID: 23526455
[TBL] [Abstract][Full Text] [Related]
20. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
